

GSK plc (the 'Company')
Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4083	7 (partnership shares)
		£16.4083	7 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	14 Ordinary Shares £16.4083	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	

a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4083	8 (partnership shares)
		£16.4083	8 (matching shares)
d)	Aggregated information		
	Aggregated volume	16 Ordinary Shares	
	Price	£16.4083	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4083	8 (partnership shares)
		£16.4083	8 (matching shares)
d)	Aggregated information		
	Aggregated volume	16 Ordinary Shares	

	Price	£16.4083
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communications and CEO Office	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4083	7 (partnership shares)
		£16.4083	7 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	14 Ordinary Shares £16.4083	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793

3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4083	8 (partnership shares)
		£16.4083	8 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	16 Ordinary Shares £16.4083	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')							
a)	Name	Regis Simard						
b)	Position/status	President, Global Supply Chain						
c)	Initial notification/ amendment	Initial notification						
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor							
a)	Name	GSK plc						
b)	LEI	5493000HZTVUYLO1D793						
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted							
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63						
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan						
c)	Price(s) and volume(s)	<table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>£16.4083</td><td>8 (partnership shares)</td></tr><tr><td>£16.4083</td><td>8 (matching shares)</td></tr></table>	Price(s)	Volume(s)	£16.4083	8 (partnership shares)	£16.4083	8 (matching shares)
Price(s)	Volume(s)							
£16.4083	8 (partnership shares)							
£16.4083	8 (matching shares)							
d)	Aggregated information Aggregated volume Price	16 Ordinary Shares £16.4083						
e)	Date of the	2025-10-09						

	transaction	
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Philip Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4083	8 (partnership shares)
		£16.4083	8 (matching shares)
d)	Aggregated information		
	Aggregated volume	16 Ordinary Shares	
	Price	£16.4083	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where	

	transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4083	8 (partnership shares)
		£16.4083	8 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	16 Ordinary Shares £16.4083	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Victoria Whyte	
b)	Position/status	SVP & Company Secretary	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4083	7 (partnership shares)
		£16.4083	7 (matching shares)
d)	Aggregated information		
	Aggregated volume Price	14 Ordinary Shares £16.4083	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

--	--	--

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFFSFLSEIFEFS